|
|
| Research article summary (published 9 Mar 2008): |
Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility.
Full Abstract
The hypersensitivity (HSR) to abacavir (ABC) pharmacogenetics (PGx) program represents the progression from an exploratory discovery to a validated biomarker. Within the program, two retrospective PGx studies were conducted to identify HIV-1 patients at increased risk for ABC HSR, a treatment-limiting and potentially life-threatening adverse event. A strong statistical association between the major histocompatibility complex allele, HLA-B*5701, and clinically diagnosed ABC HSR was identified but varied between racial populations. Subsequently, ABC skin patch testing was introduced as a research tool to supplement clinical case ascertainment. In a randomized, prospective study evaluating the clinical utility of HLA-B*5701 screening, avoidance of ABC in HLA-B*5701-positive patients significantly reduced clinically diagnosed ABC HSR and eliminated patch test-positive ABC HSR. Finally, a retrospective PGx study supports the generalizability of the association across races. Prospective HLA-B*5701 screening should greatly reduce the incidence of ABC HSR by identifying patients at high risk for ABC HSR before they are treated.
Author information
Author/s: Hughes, A R (AR); Spreen, W R (WR); Mosteller, M (M); Warren, L L (LL); Lai, E H (EH); Brothers, C H (CH); Cox, C (C); Nelsen, A J (AJ); Hughes, S (S); Thorborn, D E (DE); Stancil, B (B); Hetherington, S V (SV); Burns, D K (DK); Roses, A D (AD);
Affiliation: GlaxoSmithKline Pharmacogenetics, Research Triangle Park, NC 27709, USA. arlene.r.hughes(-atsign-)gsk.com
Journal and publication information
Publication Type: Journal Article; Review
Journal: The pharmacogenomics journal (Pharmacogenomics J), published in United States. (Language: eng)
Reference: 2008-Dec; vol 8 (issue 6) : pp 365-74
Dates: Created 2008/11/14; Completed 2009/01/07;
PMID: 18332899, status: MEDLINE (last retrieval date: 2/18/2009, IMS Date: )
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
External Links for this article
(including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MESH Headings shown below.
Related articles
These are the highest related articles currently in the database:
- Abacavir hypersensitivity reaction predicted by genetic test.
24 Mar 2004 - Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.
28 Nov 2007 - Abacavir hypersensitivity.
3 Jun 2008 - Pharmacogenomic biomarkers for prediction of severe adverse drug reactions.
5 Feb 2008 - HLA-B*5701 and abacavir hypersensitivity.
30 Oct 2004 - A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.
16 Apr 2007 - Cytokine profiling in abacavir hypersensitivity patients.
30 Dec 2007 - High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.
30 Mar 2008 - Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards.
30 Oct 2007 - HLA-B*5701 screening for hypersensitivity to abacavir.
5 Feb 2008
Related Article Map
Legend:
- FREE Full text Article.
- Abstract only.
- Title only. More help.
See a large map of 100+ related articles.